Home › Neuroblastoma › Oklahoma › Oklahoma City
Neuroblastoma clinical trials in Oklahoma City, OK
3 studies for Neuroblastoma are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RecruitingPhase 1
- University Of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- New York City, NY12 studies
- Washington, DC11 studies
- Dallas, TX10 studies
- Cincinnati, OH9 studies
- St. Louis, MO9 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Aurora, CO9 studies
- Hartford, CT8 studies
- Birmingham, AL8 studies
- Harrisburg, PA8 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer32 studies
- Ovarian Cancer29 studies
- Endometrial Cancer28 studies
- Colorectal Cancer22 studies
- Prostate Cancer22 studies
- Lung Cancer20 studies
- Breast Cancer18 studies
- Metastatic Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Cancer (all types)15 studies
- Head and Neck Squamous Cell Carcinoma14 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.